Newron Pharmaceuticals SpA (XTER:NP5) Total Liabilities: €51.19 Mil (As of Dec. 2025)


XTER:NP5 Newron Pharmaceuticals SpA XTER:NP5
50 GF Score
Price €13.30
GF Value €14.14
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Newron Pharmaceuticals SpA Total Liabilities?

Newron Pharmaceuticals SpA XTER:NP5 -4.32% 50 Total Liabilities is €51.19 Mil as of Dec. 2025. GuruFocus rates XTER:NP5 with a GF Score™ of 50/100 and a GF Value™ of €14.14 (Fairly Valued). The stock has 5 warning signs investors should review.

Newron Pharmaceuticals SpA's Total Liabilities for the quarter that ended in Dec. 2025 was €51.19 Mil.

Newron Pharmaceuticals SpA's quarterly Total Liabilities declined from Dec. 2024 (€62.45 Mil) to Jun. 2025 (€59.81 Mil) and declined from Jun. 2025 (€59.81 Mil) to Dec. 2025 (€51.19 Mil).

Newron Pharmaceuticals SpA's annual Total Liabilities increased from Dec. 2023 (€55.77 Mil) to Dec. 2024 (€62.45 Mil) but then declined from Dec. 2024 (€62.45 Mil) to Dec. 2025 (€51.19 Mil).

Newron Pharmaceuticals SpA Total Liabilities Historical Data

* Premium members only.

The historical data trend for Newron Pharmaceuticals SpA's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Newron Pharmaceuticals SpA Total Liabilities Chart

Newron Pharmaceuticals SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 47.38 51.23 55.77 62.45 51.19

Newron Pharmaceuticals SpA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 55.77 55.77 62.45 59.81 51.19
XTER:NP5
50GF Score
Newron Pharmaceuticals SpA XTER:NP5
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Newron Pharmaceuticals SpA Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Newron Pharmaceuticals SpA's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=50.131+(0.583+-2.4424906541753E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.476+0)
=51.19

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=40.055--11.135
=51.19

Newron Pharmaceuticals SpA's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=50.131+(0.583+-2.4424906541753E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.476+0)
=51.19

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=40.055--11.135
=51.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €51.19 Mil mean?
Newron Pharmaceuticals SpA (XTER:NP5) has a Total Liabilities of €51.19 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Newron Pharmaceuticals SpA and its competitors.
Is Newron Pharmaceuticals SpA's Total Liabilities too high?
Newron Pharmaceuticals SpA's current Total Liabilities is €51.19 Mil. Overall, Newron Pharmaceuticals SpA has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Newron Pharmaceuticals SpA's Total Liabilities compare to VRTX and REGN?
Newron Pharmaceuticals SpA's Total Liabilities of €51.19 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Newron Pharmaceuticals SpA and its competitors. Newron Pharmaceuticals SpA's current Total Liabilities is €51.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newron Pharmaceuticals SpA stock overvalued right now?
Based on GuruFocus' analysis, Newron Pharmaceuticals SpA (XTER:NP5) is currently considered Fairly Valued. The stock's GF Value™ is €14.14, compared to a current price of €13.30 — trading 5.9% below its estimated fair value. The current Total Liabilities is €51.19 Mil. Newron Pharmaceuticals SpA's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Newron Pharmaceuticals SpA (XTER:NP5), the current Total Liabilities is €51.19 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Newron Pharmaceuticals SpA (XTER:NP5) Overvalued in 2026?

Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued. The current stock price of €13.30 is trading 5.9% below its estimated GF Value™ of €14.14. GuruFocus considers Newron Pharmaceuticals SpA to be Fairly Valued.

Key valuation signals for XTER:NP5:

  • Total Liabilities: €51.19 Mil
  • GF Value™: €14.14 vs. price of €13.30 (5.9% below fair value)
  • GF Score™: 50/100 with 5 warning signs

No single metric tells the full story. See the XTER:NP5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Newron Pharmaceuticals SpA Business Description

Address Via Antonio Meucci 3, Bresso, Milan, ITA, 20091
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
50GF Score

Get the complete analysis for XTER:NP5

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.30
Price
€14.14
GF Value